DEF: Assertio Holdings Schedules 2026 Virtual Annual Meeting

Assertio Holdings, Inc. announced its 2026 Virtual Annual Meeting of Stockholders, set for May 5, 2026, to elect directors, approve an incentive plan amendment, and ratify auditor appointments.

Summary

• Assertio Holdings, Inc. is holding its Annual Meeting of Stockholders virtually on May 5, 2026, at 11:30 a.m. Central Time.
• The meeting will be conducted exclusively via live audio webcast, allowing stockholders to participate from any location.
• Key agenda items include the election of six directors, approval of an amendment to increase shares available under the 2014 Omnibus Incentive Plan, an advisory vote on executive compensation, and ratification of Grant Thornton LLP as the independent auditor for fiscal year 2026.
• Stockholders of record as of March 9, 2026, are entitled to vote.
• The company implemented a 1-for-15 reverse stock split on December 26, 2025, with all share data retrospectively adjusted.
• The company has settled several legal matters, including a DOJ False Claims Act lawsuit and legacy antitrust and securities class actions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance procedures and a focus on long-term incentive alignment, with some positive operational and legal developments offset by a GAAP net loss.

Positives

• The company has settled significant legal matters, including a DOJ False Claims Act qui tam lawsuit, the last remaining Glumetza antitrust action, and Spectrum's legacy Luo securities class action, and obtained dismissal of the Edwards securities class action, which is expected to reduce future legal costs.
• The company appointed a new CEO, Mark L. Reisenauer, in October 2025, with extensive experience in building franchises and products.
• Key integration efforts are advancing to consolidate operations and align products, aiming for greater efficiency and cost savings.
• The company amended its Manufacturing and Supply Agreement with Hanmi Pharmaceutical Co. Ltd. for Rolvedon, fixing the price for the remaining term.
• The company simplified its corporate holdings by divesting its subsidiary Assertio Therapeutics, removing it from opioid-related litigation.
• For fiscal year 2025, the company reported product sales of $117.1 million, with Rolvedon contributing $68.2 million.
• The company achieved 100% of its corporate financial goals for 2025, with Net Product Revenue of $117 million and adjusted EBITDA of $23 million.

Negatives

• The company reported a full-year GAAP net loss of $30.4 million for fiscal year 2025.
• The company's 2025 performance on corporate business goals was 90%, resulting in an overall attainment of 95% for the bonus plan.
• The company's 2025 performance on 'People and Culture' business goals was 40%.

Risks

• Forward-looking statements are subject to substantial risks and uncertainties, including those described in the company's most recent Form 10-K and other SEC filings.
• The company's ability to attract and retain talent may be impacted if it cannot offer competitive equity awards, potentially affecting its ability to achieve financial goals.
• The proposed increase in shares available under the 2014 Omnibus Incentive Plan could lead to potential dilution to common shareholders.

Future Outlook

The company is seeking stockholder approval to increase the number of shares available under its 2014 Omnibus Incentive Plan by 400,000 shares, which is expected to provide flexibility to grant equity-based awards through 2027. The company also expects to file a registration statement on Form S-8 for these shares by the end of 2026. The next advisory vote on executive compensation will occur at the 2027 Annual Meeting.

Management Comments

• The Board of Directors believes that a virtual annual meeting enables stockholders to participate fully and equally from any location around the world, providing the same rights and opportunities as an in-person meeting.
• The company strives to align executive compensation with business results and stockholder interests, offering a competitive program that allows named executive officers to share in financial success when performance goals are met.
• The company believes that equity ownership by employees correlates with increased engagement, which is a key factor in achieving future financial goals and creating stockholder value.
• The company believes that the ability to grant competitive equity awards is a necessary and powerful recruiting and retention tool.

Industry Context

StockSavvy.ai notes that Assertio Holdings' proxy statement reflects common practices in the life sciences and pharmaceutical industry, particularly regarding executive compensation, equity incentive plans, and corporate governance. The focus on increasing the share pool for equity awards is a standard approach to attract and retain talent in a competitive market. The company's efforts to settle legal matters and streamline operations are also typical strategic moves for companies in this sector aiming to improve financial performance and shareholder value.

Comparison to Industry Standards

• The proposed increase of 400,000 shares under the 2014 Omnibus Incentive Plan represents approximately 6.2% of the company's outstanding shares as of March 9, 2026. The maximum potential dilution from this increase is estimated at 5.8%, assuming all shares are issued as stock options. This dilution level is considered consistent with market practice by the Compensation Committee.
• The company's burn rate for fiscal 2025 was 7.5% (including PSUs and performance-based options at grant) and 2.6% (including vested PSUs, vested performance-based options, and forfeitures/expirations). These figures are within the typical range for companies in the biopharmaceutical sector, which often have burn rates between 2% and 10%.
• The company's overhang is projected to be approximately 22.4% if the share increase is approved. This percentage is within the typical range for companies in the industry, though it can vary significantly based on the company's stage of development and capital needs.
• The company's executive compensation philosophy, which emphasizes aligning pay with business results and stockholder interests through a mix of base salary, annual bonuses, and long-term equity incentives, is consistent with industry standards. The use of metrics like Net Product Revenue and adjusted EBITDA for bonus calculations is also common.

Management Changes

Corporate Governance

Legal Proceedings

• The company has settled the previously disclosed DOJ False Claims Act qui tam lawsuit.
• The company has settled the last remaining Glumetza antitrust action.
• The company has settled Spectrum's legacy Luo securities class action.
• The company obtained the dismissal of the Edwards securities class action.
• The company transferred all interests in its subsidiary Assertio Therapeutics, meaning neither the company nor its current subsidiaries are defendants in any opioid-related litigation.

Related Party Transactions

• The brother-in-law of Paul Schwichtenberg (President and Chief Operating Officer) served as Associate Director, Operations and then Executive Director, Operations, earning above the $120,000 reporting threshold in 2025, commensurate with similarly situated employees.

Stakeholder Impact

• Shareholders: The proposed increase in the equity incentive plan shares could lead to dilution, but is intended to drive long-term value creation. The settlement of legal matters is expected to reduce future legal costs.
• Employees: The equity incentive plan aims to attract, retain, and motivate employees by linking their compensation to company performance and stock value.
• Management: Executive compensation is designed to align with business results and stockholder interests, with a significant portion in long-term incentives.
• Creditors: The company's financial performance, including its GAAP net loss, will be a key consideration for creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals presented at the Annual Meeting.
• The company will file a registration statement on Form S-8 covering the new shares reserved for issuance under the 2014 Plan by the end of 2026.
• The next advisory vote on executive compensation will occur at the 2027 Annual Meeting of Stockholders.
• The next required vote on the frequency of advisory votes on executive compensation will occur at the 2029 Annual Meeting of Stockholders.

Key Dates

Recommendation

The filing indicates a company focused on operational improvements and legal settlements, with a clear strategy for long-term incentive alignment. However, the ongoing GAAP net loss and the need for additional equity to retain talent suggest a period of continued investment and potential dilution. While positives exist, the financial performance does not yet warrant a strong buy or sell recommendation, making 'hold' appropriate for a seasoned investor monitoring progress.

Keywords

Proxy Statement, Annual Meeting, Stockholders, Virtual Meeting, Election of Directors, Incentive Plan, Executive Compensation, Independent Auditor, Grant Thornton LLP, Assertio Holdings, Equity Awards, Reverse Stock Split